Research progress on the oncogenic role of long non-coding RNA prostate cancer associated transcript 1

LI Yuran; HUANG Yu; CHEN Jing; SHEN Weigan

doi:10.7619/jcmp.20243821

Journal of Clinical Medicine in Practice > 2025 > 29(2): 138-142. > DOI: 10.7619/jcmp.20243821

LI Yuran, HUANG Yu, CHEN Jing, SHEN Weigan. Research progress on the oncogenic role of long non-coding RNA prostate cancer associated transcript 1[J]. Journal of Clinical Medicine in Practice, 2025, 29(2): 138-142. DOI: 10.7619/jcmp.20243821

Citation:

PDF (1280 KB)

Research progress on the oncogenic role of long non-coding RNA prostate cancer associated transcript 1

Medical College of Yangzhou University, Yangzhou, Jiangsu, 225009

More Information

Received Date: August 26, 2024
Revised Date: December 12, 2024

Graphical Abstract

Abstract

Abstract

Long non-coding RNA (lncRNA) play crucial roles in cell development, differentiation, and proliferation, serving as one of key molecules in regulating gene expression. Studies have shown that abnormal expression of lncRNAs is closely associated with the onset, malignant progression, and metastasis of various tumors. Prostate cancer associated transcript 1 (PCAT1), as an important member of lncRNA, has been demonstrated to be highly expressed in multiple cancers and involved in multiple biological regulatory processes, thereby promoting cancer development. This article reviewed the roles, mechanisms, and regulatory targets of lncRNA PCAT1 in cancer initiation and progression, aiming to provide a reference for subsequent research.
- long non-coding RNA,
- prostate cancer associated transcript 1,
- tumor,
- tumor marker,
- signaling pathway,
- molecular mechanism

FullText(HTML)

References (43)

References

[1]	GEISLER S, COLLER J. RNA in unexpected places: long non-coding RNA functions in diverse cellular contexts[J]. Nat Rev Mol Cell Biol, 2013, 14: 699-712. doi: 10.1038/nrm3679
[2]	周扬. LncRNA PCAT1通过调控RNA m6A修饰促进胰腺癌进程及雷公藤红素干预的研究[D]. 扬州: 扬州大学, 2023.
[3]	XING C, SUN S G, YUE Z Q, et al. Role of lncRNA LUCAT1 in cancer[J]. Biomed Pharmacother, 2021, 134: 111158. doi: 10.1016/j.biopha.2020.111158
[4]	LI J, LI Y J, WANG B, et al. LncRNA-PCAT-1 promotes non-small cell lung cancer progression by regulating miR-149-5p/LRIG2 axis[J]. J Cell Biochem, 2019, 120(5): 7725-7733. doi: 10.1002/jcb.28046
[5]	WANG M, HU H, WANG Y, et al. Long non-coding RNA TUG1 mediates 5-fluorouracil resistance by acting as a CeRNA of miR-197-3p in colorectal cancer[J]. J Cancer, 2019, 10(19): 4603-4613. doi: 10.7150/jca.32065
[6]	VILLARREAL L, WITZANY G. Self-empowerment of life through RNA networks, cells and viruses[J]. F1000Res, 2023, 12: 138. doi: 10.12688/f1000research.130300.2
[7]	YANG M L, HUANG Z, WU L N, et al. lncRNA-PCAT1 rs2632159 polymorphism could be a biomarker for colorectal cancer susceptibility[J]. Biosci Rep, 2019, 39(7): BSR20190708. doi: 10.1042/BSR20190708
[8]	ZHANG Y, WU Y, JIA Z, et al. Long non-coding RNA polymorphisms on 8q24 are associated with the prognosis of gastric cancer in a Chinese population[J]. PeerJ, 2020, 8: e8600. doi: 10.7717/peerj.8600
[9]	ZANG Q, XU L, LI J, et al. GATA6 activated long non-coding RNA PCAT1 maintains stemness of non-small cell lung cancer by mediating FRK[J]. J BUON, 2020, 25(5): 2371-2381.
[10]	YUAN Y, WANG Q, MA S L, et al. lncRNA PCAT-1 interacting with FZD6 contributes to the malignancy of acute myeloid leukemia cells through activating Wnt/β-catenin signaling pathway[J]. Am J Transl Res, 2019, 11(11): 7104-7114.
[11]	DING C, WEI R, RODRÍGUEZ R A, et al. LncRNA PCAT-1 plays an oncogenic role in epithelial ovarian cancer by modulating cyclinD1 biological regu[J]. Int J Clin Exp Pathol, 2019, 12(6): 2148-2156.
[12]	LI H, MA X, YANG D, et al. PCAT-1 contributes to cisplatin resistance in gastric cancer through epigenetically silencing PTEN via recruiting EZH2[J]. J Cell Biochem, 2020, 121(2): 1353-1361. doi: 10.1002/jcb.29370
[13]	ZANG B, ZHAO J, CHEN C. LncRNA PCAT-1 promoted ESCC progression via regulating ANXA10 expression by sponging miR-508-3p[J]. Cancer Manag Res, 2019, 11: 10841-10849. doi: 10.2147/CMAR.S233983
[14]	SADI KHOSROSHAHI N, KOULAEIZADEH S, ABDI A, et al. Upregulation of long noncoding RNA PCAT1 in Iranian patients with colorectal cancer and its performance as a potential diagnostic biomarker[J]. Genet Test Mol Biomarkers, 2024, 28(2): 65-69. doi: 10.1089/gtmb.2023.0676
[15]	ZHANG S, ZHU K, HAN Q, et al. lncRNA PCAT1 might coordinate ZNF217 to promote CRC adhesion and invasion through regulating MTA2/MTA3/Snai1/E-cadherin signaling[J]. Cell Mol Biol: Noisy-le-grand, 2022, 67(4): 1-9.
[16]	SUN H, SUN X, ZHANG H, et al. LncRNA-PCAT1 controls the growth, metastasis and drug resistance of human colon cancer cells[J]. j buon, 2020, 25(5): 2180-2185.
[17]	FANG X, XU Y, LI K, et al. Exosomal lncRNA PCAT1 promotes tumor circulating cell-mediated colorectal cancer liver metastasis by regulating the activity of the miR-329-3p/netrin-1-CD146 complex[J]. J Immunol Res, 2022, 2022: 9916228.
[18]	WANG A H, FAN W J, FU L, et al. LncRNA PCAT-1 regulated cell proliferation, invasion, migration and apoptosis in colorectal cancer through targeting miR-149-5p[J]. Eur Rev Med Pharmacol Sci, 2019, 23(19): 8310-8320.
[19]	HUANG L J, WANG Y, CHEN J, et al. Long noncoding RNA PCAT1, a novel serum-based biomarker, enhances cell growth by sponging miR-326 in oesophageal squamous cell carcinoma[J]. Cell Death Dis, 2019, 10: 513. doi: 10.1038/s41419-019-1745-4
[20]	GUO Y, YUE P, WANG Y, et al. PCAT-1 contributes to cisplatin resistance in gastric cancer through miR-128/ZEB1 axis[J]. Biomed Pharmacother, 2019, 118: 109255. doi: 10.1016/j.biopha.2019.109255
[21]	AKHGARI H, SHOKRI N, DEHGHANZADEH P, et al. Expression pattern of PCAT1, PCAT2, and PCAT5 lncRNAs and their value as diagnostic biomarkers in patients with gastric cancer[J]. Pathol Res Pract, 2023, 248: 154654. doi: 10.1016/j.prp.2023.154654
[22]	SUN D, ZHAO Y, WANG W, et al. PCAT1 induced by transcription factor YY1 promotes cholangiocarcinoma proliferation, migration and invasion by sponging miR-216a-3p to up-regulate oncogene BCL3[J]. Biol Chem, 2021, 402(2): 207-219. doi: 10.1515/hsz-2020-0276
[23]	SHANG Z, YU J, SUN L, et al. LncRNA PCAT1 activates AKT and NF-κB signaling in castration-resistant prostate cancer by regulating the PHLPP/FKBP51/IKKα complex[J]. Nucleic Acids Res, 2019, 47(8): 4211-4225. doi: 10.1093/nar/gkz108
[24]	JIANG X, GUO S, XU M, et al. TFAP2C-Mediated lncRNA PCAT1 Inhibits Ferroptosis in Docetaxel-Resistant Prostate Cancer Through c-Myc/miR-25-3p/SLC7A11 Signaling[J]. Front Oncol, 2022, 12: 862015. doi: 10.3389/fonc.2022.862015
[25]	LIU X L, LIU H M, HAN N, et al. PCAT1 promotes the proliferative and migratory potentials of ovarian cancer via targeting NEK2[J]. Eur Rev Med Pharmacol Sci, 2019, 23(19): 8239-8248.
[26]	GU L P, JIN S, XU R C, et al. Long non-coding RNA PCAT-1 promotes tumor progression by inhibiting miR-129-5p in human ovarian cancer[J]. Arch Med Sci, 2019, 15(2): 513-521. doi: 10.5114/aoms.2018.75534
[27]	GE X, GU Y, LI D, et al. Knockdown of lncRNA PCAT1 enhances radiosensitivity of cervical cancer by regulating miR-128/GOLM1 axis[J]. Onco Targets Ther, 2020, 13: 10373-10385. doi: 10.2147/OTT.S263728
[28]	ZHAO X, FAN Y, LU C, et al. PCAT1 is a poor prognostic factor in endometrial carcinoma and associated with cancer cell proliferation, migration and invasion[J]. Bosn J Basic Med Sci, 2019, 19(3): 274-281.
[29]	WANG J, CHEN X, HU H, et al. PCAT-1 facilitates breast cancer progression via binding to RACK1 and enhancing oxygen-independent stability of HIF-1α[J]. Mol Ther Nucleic Acids, 2021, 24: 310-324. doi: 10.1016/j.omtn.2021.02.034
[30]	TANG W, LU G, JI Y, et al. Long non-coding RNA PCAT1 sponges miR-134-3p to regulate PITX2 expression in breast cancer[J]. Mol Med Rep, 2022, 25(3): 75. doi: 10.3892/mmr.2022.12591
[31]	HUANG T, ZHANG J. Biological functions of PCAT-1/SOX4 in cell proliferation and invasion of breast cancer[J]. Cell Mol Biol: Noisy-le-grand, 2024, 70(4): 90-94.
[32]	SUR S, NAKANISHI H, STEELE R, et al. Depletion of PCAT-1 in head and neck cancer cells inhibits tumor growth and induces apoptosis by modulating c-Myc-AKT1-p38 MAPK signalling pathways[J]. BMC Cancer, 2019, 19(1): 354. doi: 10.1186/s12885-019-5562-z
[33]	HU W, DONG N, HUANG J, et al. Long non-coding RNA PCAT1 promotes cell migration and invasion in human laryngeal cancer by sponging miR-210-3p[J]. j buon, 2019, 24(6): 2429-2434.
[34]	SHEN X, SHEN P, YANG Q, et al. Knockdown of long non-coding RNA pcat-1 inhibits myeloma cell growth and drug resistance via p38 and jnk mapk pathways[J]. J Cancer, 2019, 10(26): 6502-6510. doi: 10.7150/jca.35098
[35]	SHEN X, KONG S, YANG Q, et al. PCAT-1 promotes cell growth by sponging miR-129 via MAP3K7/NF-κB pathway in multiple myeloma[J]. J Cell Mol Med, 2020, 24(6): 3492-3503. doi: 10.1111/jcmm.15035
[36]	GAO Y, ZHANG N, ZENG Z, et al. LncRNA PCAT1 activates SOX2 and suppresses radioimmune responses via regulating cGAS/STING signalling in non-small cell lung cancer[J]. Clin Transl Med, 2022, 12(4): e792. doi: 10.1002/ctm2.792
[37]	LIU S Y, ZHAO Z Y, QIAO Z, et al. LncRNA PCAT1 interacts with DKC1 to regulate proliferation, invasion and apoptosis in NSCLC cells via the VEGF/AKT/Bcl2/Caspase9 pathway[J]. Cell Transplant, 2021, 30: 963689720986071. doi: 10.1177/0963689720986071
[38]	TIAN R, ZHANG C, XIONG F, et al. PCAT1/miR-129/ABCB1 axis confers chemoresistance in non-small cell lung cancer[J]. Front Biosci: Landmark Ed, 2020, 25(5): 948-960. doi: 10.2741/4842
[39]	WANG S, LIU C, LEI Q, et al. Relationship between long non-coding RNA PCAT-1 expression and gefitinib resistance in non-small-cell lung cancer cells[J]. Respir Res, 2021, 22(1): 146. doi: 10.1186/s12931-021-01719-7
[40]	CHANG L, JIA D L, CAO C S, et al. LncRNA PCAT-1 promotes the progression of osteosarcoma via miR-508-3p/ZEB1 axis[J]. Eur Rev Med Pharmacol Sci, 2021, 25(6): 2517-2527.
[41]	ZHANG P H, LIU Y, FU C Y, et al. Knockdown of long non-coding RNA PCAT1 in glioma stem cells promotes radiation sensitivity[J]. Med Mol Morphol, 2019, 52(2): 114-122. doi: 10.1007/s00795-018-0209-8
[42]	POKORNÁ M, GERNÁ M, BOUSSIOS S, et al. lncRNA biomarkers of glioblastoma multiforme[J]. Biomedicines, 2024, 12(5): 932. doi: 10.3390/biomedicines12050932
[43]	DOMVRI K, PETANIDIS S, ANESTAKIS D, et al. Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation[J]. Oncotarget, 2020, 11(29): 2847-2862. doi: 10.18632/oncotarget.27675

[1]	MEI Hanwei, QIU Minghan, SONG Teng, WU Shan, ZHAO Ke, ZOU Dandan, LI Shuping, HE Guopping, ZHAO Xuanzhu, WANG Huaqing. Correlations between TCM syndromes and clinical factors after colorectal cancer surgery[J]. Journal of Clinical Medicine in Practice, 2023, 27(2): 62-66. DOI: 10.7619/jcmp.20223015
[2]	SHEN Xiaohua, LU Gendi, JIANG Guojing, HU Li, TAN Xiaohong. Effect of inducing yang into yin massage on sleep disturbance and negative emotion in puerperae with syndrome of deficiency of heart and spleen after cesarean section[J]. Journal of Clinical Medicine in Practice, 2022, 26(9): 54-58. DOI: 10.7619/jcmp.20214668
[3]	ZHANG Chao, WEI Yuanwei. Effect of modified Shipi Yin combined with acupoint application in patients with chronic heart failure differentiated as heart-yang deficiency syndrome[J]. Journal of Clinical Medicine in Practice, 2020, 24(24): 64-66,69. DOI: 10.7619/jcmp.202024019
[4]	GU Wenyan, WANG Li, MA Caiyu, DING Chunlei, QIAN Fenghua, ZHAO Lei. Effect of retention enema by Shengjiang Powder in treating ventilator-associated pneumonia differentiated as phlegm-heat congesting in lungs syndrome on TCM syndrome scores, curative effect and related inflammatory factors[J]. Journal of Clinical Medicine in Practice, 2020, 24(1): 69-72. DOI: 10.7619/jcmp.202001018
[5]	MAO Xue, ZHAO Xin. Effect of Qingfei Tongfu Decoction on the lung function, score of TCM syndrome and levels of inflammatory factors in patients with severe pneumonia differentiated as syndrome of obstruction of phlegm-heat in lung[J]. Journal of Clinical Medicine in Practice, 2019, 23(16): 51-53, 57. DOI: 10.7619/jcmp.201916014
[6]	LIU Chenxia, GENG Feng. Effect of Wendan Decoction on score of TCM syndromes in patients with gastric distention and fullness[J]. Journal of Clinical Medicine in Practice, 2019, 23(14): 17-20. DOI: 10.7619/jcmp.201914004
[7]	YU Jiafeng, ZHU Hui, GUO Yaoyao, LI Xia, LIU Kefu, XIE Ping. Values of transcranial Doppler ultrasound classificationand TCM syndromes in the treatment of patients with vertebrobasilar insufficiency vertigo[J]. Journal of Clinical Medicine in Practice, 2019, 23(11): 11-13. DOI: 10.7619/jcmp.201911003
[8]	CHEN Shujian. Effect of activating blood and eliminating phlegm on TCM syndrome scores and lung function in outpatients with bronchial asthma[J]. Journal of Clinical Medicine in Practice, 2019, (1): 52-55. DOI: 10.7619/jcmp.201901014
[9]	GUO Feng, ZHANG Shuli, YIN Xiaoying. Effect of routine treatment of western medicine combined with nasal feeding of qingqi liangying decoction on inflammatory reaction, pulmonary function and TCM syndrome score in emergency patients with ventilator-associated pneumonia[J]. Journal of Clinical Medicine in Practice, 2018, (7): 45-47,52. DOI: 10.7619/jcmp.201807012
[10]	LU Jun. Efficacy of syndrome differentiation with TCM plus western medicine in treatment of elderly patients with sensorineural deafness[J]. Journal of Clinical Medicine in Practice, 2016, (19): 76-78. DOI: 10.7619/jcmp.201619022

Cited By

Get Citation

PDF

XML

Article views (88) PDF downloads (22)

Turn off MathJax

Article Contents

Abstract

References

Research progress on the oncogenic role of long non-coding RNA prostate cancer associated transcript 1

Abstract

References

Related Articles

Catalog

Research progress on the oncogenic role of long non-coding RNA prostate cancer associated transcript 1

Abstract

References

Related Articles

Catalog

Export File

Citation

Format

Content